Evidence map›Paper›PMID 37962671›Full record

ArticleHuman genetics2023

Phenotypic correlates of structural and functional protein impairments resultant from ALDH5A1 variants.

Itay Tokatly Latzer, Jean-Baptiste Roullet, Samuele Cesaro, Melissa L DiBacco, Erland Arning, Alexander Rotenberg, Henry H C Lee, Thomas Opladen, Kathrin Jeltsch, Àngels García-Cazorla and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Central Dysmyelination in SSADH-Deficient Humans and Mice.Annals of clinical and translational neurology · 2025
    Observational
  4. A crucial active site network of titratable residues guides catalysis and NADProtein science : a publication of the Protein Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Itay Tokatly LatzerDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0003-3132-1379
Jean-Baptiste RoulletDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.ORCID http://orcid.org/0000-0001-7403-3620
Samuele CesaroDepartment of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Strada Le Grazie 8, 37134, Verona, VR, Italy.ORCID http://orcid.org/0009-0005-0922-7652
Melissa L DiBaccoDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-8046-8740
Erland ArningInstitute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-0934-0808
Alexander RotenbergDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-6495-5928
Henry H C LeeF.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0003-4975-7330
Thomas OpladenDivision of Neuropediatrics and Metabolic Medicine, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Kathrin JeltschDivision of Neuropediatrics and Metabolic Medicine, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Àngels García-CazorlaNeurometabolic Unit, Neurology Department, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain.
Natalia Juliá-PalaciosNeurometabolic Unit, Neurology Department, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain.
K Michael GibsonDepartment of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Mariarita Bertoldi *Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Strada Le Grazie 8, 37134, Verona, VR, Italy. mita.bertoldi@univr.it.ORCID http://orcid.org/0000-0002-2337-9928
Phillip L PearlDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA. Phillip.Pearl@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-6373-1068

Funding

Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA MetabolismR01HD091142 · NICHD · WASHINGTON STATE UNIVERSITY · PI Phillip Lawrence Pearl · 2018 to 2026
$5.3M
Eunice Kennedy Shriver National Institute of Child Health and Human Development 1R01HD091142NICHD NIH HHS R01 HD091142
6 · The paper itself

Abstract

To investigate the genotype-to-protein-to-phenotype correlations of succinic semialdehyde dehydrogenase deficiency (SSADHD), an inherited metabolic disorder of γ-aminobutyric acid catabolism. Bioinformatics and in silico mutagenesis analyses of ALDH5A1 variants were performed to evaluate their impact on protein stability, active site and co-factor binding domains, splicing, and homotetramer formation. Protein abnormalities were then correlated with a validated disease-specific clinical severity score and neurological, neuropsychological, biochemical, neuroimaging, and neurophysiological metrics. A total of 58 individuals (1:1 male/female ratio) were affected by 32 ALDH5A1 pathogenic variants, eight of which were novel. Compared to individuals with single homotetrameric or multiple homo and heterotetrameric proteins, those predicted not to synthesize any functional enzyme protein had significantly lower expression of ALDH5A1 (p = 0.001), worse overall clinical outcomes (p = 0.008) and specifically more severe cognitive deficits (p = 0.01), epilepsy (p = 0.04) and psychiatric morbidity (p = 0.04). Compared to individuals with predictions of having no protein or a protein impaired in catalytic functions, subjects whose proteins were predicted to be impaired in stability, folding, or oligomerization had a better overall clinical outcome (p = 0.02) and adaptive skills (p = 0.04). The quantity and type of enzyme proteins (no protein, single homotetramers, or multiple homo and heterotetramers), as well as their structural and functional impairments (catalytic or stability, folding, or oligomerization), contribute to phenotype severity in SSADHD. These findings are valuable for assessment of disease prognosis and management, including patient selection for gene replacement therapy. Furthermore, they provide a roadmap to determine genotype-to-protein-to-phenotype relationships in other autosomal recessive disorders.

Indexed as

Amino Acid Metabolism, Inborn ErrorsChildDevelopmental DisabilitiesFemaleHumansMalePhenotypeSuccinate-Semialdehyde DehydrogenaseALDH5A1 protein, humanSuccinate-Semialdehyde Dehydrogenase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.